International Journal of Medical Laboratory Research (IJMLR)

LEVELS OF TROPNIN AND CREATINE KINASE MB IN MYOCARDIAL INFARCTION PATIENTS

 

Tariq Elfatih Elmisbah, Mohammed Aiderous

 

ABSTRACT:

Background.Myocardial infarction (MI) commonly known as a heart attack occurs when blood flow stops to part of the heart causing damage to the heart muscle. Troponin, or troponin  complex, is acomplex of three regulatory proteins( troponinC, troponon1, and troponin T),that is integral to cardiac muscles. An increased level of the cardiac protein isoform of troponin circulating in the blood has been showen to be a biomarker of heart disorders, the most important of which is myocardialinfarction. Creatine kinase –MB is an enzyme found in the heart and rises when heart muscle is damaged. Study design. This study was designed  asa case control study in aceer state, Saudi Arabia to determine the frequency of determine the levels of tropnine and creatine MB in myocardial infarction patients. Materials and methods. One hundred fifty Saudi myocardial infarction patients admitted to KhamisMushiat central hospital in KSAduring the period from March 2016-april 2017 were recruited to participate in this study as well as fifty apparently healthy volunteers were enrolled as a control group. A venous blood 2.7ml sample was collected in a plastic tube vacationer containing sodium citrate anticoagulant for immunological analysis Non-probability sampling method was used. A sandwich electrochemiluminescence immunoassay which employs 2 monoclonal antibodies was used. Results.  Results showed that the mean of troponin among study sample was increased in compared to control (P.value issignificant), and also the study showed that the mean of creatine kinase MB levels was increased in compared with control(P.value is significant). Conclusion. This study proved that the levels of troponine and creatine kinase were increased in myocardial infarction patients.

​

KEY WORDS: Myocardial infarction, troponin, creatine kinase MB

​

REFERENCES:

1. Bjork, I; Olson, JE (1997). Antithrombin, A bloody important serpin (in Chemistry and Biology of Serpins). Plenum Press. pp. 17–33. ISBN 0-306-45698-2.

2. Collen D, Schetz J, de Cock F, Holmer E, Verstraete M (1977). "Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration". Eur. J. Clin. Invest 7 (1): 27–35. doi:10.1111/j.1365-2362.1977.tb01566.x. PMID 65284.

3. Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U (1983). "Molar antithrombin concentration in normal human plasma". Haemostasis 13 (6): 363–368. doi:10.1159/000214823. PMID 6667903.

4. Jordan RE (1983). "Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism". Arch. Biochem. Biophys 227 (2): 587–595. doi:10.1016/0003-9861(83)90488-5. PMID 6607710

5. Olson ST, Björk I (1994). "Regulation of thrombin activity by antithrombin and heparin". Sem. Thromb. Hemost. 20 (4): 373–409. doi:10.1055/s-2007-1001928. PMID 7899869.

6. Brennan SO, George PM, Jordan RE (1987). "Physiological variant of antithrombin-III lacks carbohydrate side-chain at Asn 135". FEBS Lett 219 (2): 431–436. doi:10.1016/0014-5793(87)80266-1. PMID 3609301.

7. Persson E, Bak H, Olsen OH (2001). "Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity". J. Biol. Chem. 276 (31): 29195–29199. doi:10.1074/jbc.M102187200. PMID 11389142.

8. Stephens AW, Siddiqui A, Hirs CH (1987). "Expression of functionally active human antithrombin III". Proceedings of the National Academy of Sciences of the United States of America 84 (11): 3886–3890. doi:10.1073/pnas.84.11.3886. PMC 304981. PMID 3473488

9. Zettlmeissl G, Conradt HS, Nimtz M, Karges HE (1989). "Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells". J. Biol. Chem. 264 (35): 21153–21159. PMID 2592368.

10. Gillespie LS, Hillesland KK, Knauer DJ (1991). "Expression of biologically active human antithrombin III by recombinant baculovirus in Spodopterafrugiperda cells". J. Biol. Chem. 266 (6): 3995–4001. PMID 1995647.

11. Ersdal-Badju E, Lu A, Peng X, Picard V, Zendehrouh P, Turk B, Björk I, Olson ST, Bock SC (1995). "Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells". Biochem. J. 310 (Pt 1): 323–330. PMC 1135891. PMID 7646463..

12. Ogston D, Murray J, Crawford GP (1976). "Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin". Thromb. Res. 9 (3): 217–222. doi:10.1016/0049-3848(76)90210-3. PMID 982345.

13. Danielsson A, Björk I (1980). "Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor". FEBS Lett 119 (2): 241–244. doi:10.1016/0014-5793(80)80262-6. PMID 7428936.

14. Chang WS, Wardell MR, Lomas DA, Carrell RW (1996). "Probing serpin reactive-loop conformations by proteolytic cleavage". Biochem. J. 314 (2): 647–653. PMC 1217096. PMID 8670081.

15. "What Are the Signs and Symptoms of Coronary Heart Disease?".http://www.nhlbi.nih.gov/. September 29, 2014. Retrieved 23 February 2015.

16. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology, (ESC); Steg, PG; James, SK; Atar, D; Badano, LP;